Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

DEA Issues Final Rule on Partial Filling of Schedule II Prescriptions

Posted 7/23/2023

July 21, 2023 - On July 22, 2016, the Comprehensive Addiction and Recovery Act of 2016 (CARA) was signed into law. One provision of CARA amended the Controlled Substances Act to allow the partial filling of schedule II prescriptions under certain conditions. DEA last week amended its regulations to conform to this statutory provision, as well as to provide direction on gaps not addressed by the legislation.

This Final Rule becomes effective 30 days after publication in the Federal Register. A copy of the notice is found here.

Changes will allow a pharmacist to partially fill a Schedule II prescription when requested by the prescribing practitioner or the patient provided that all of the following conditions are satisfied:

(1) The partial filling must not be prohibited by State law;

(2) The prescription must be written and filled in accordance with the CSA, DEA regulations, and State law; and

(3) The total quantity dispensed in all partial fillings must not exceed the total quantity prescribed.

Back to all news

Sponsor Spotlight

COMPASS Pathways

COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more

All Sponsors